文献速递肝病

原发性硬化性胆管炎患者肝移植前后维生素B6缺乏的临床与生化影响

Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation.
PubMed 文献 · J Hepatol · 2023-06-14

在多中心横断面和纵向队列中,17-38%的原发性硬化性胆管炎(PSC)患者血浆磷酸吡哆醛(PLP)低于维生素B6缺乏的生化定义,且该缺乏在PSC中比无PSC的炎症性肠病和原发性胆汁性胆管炎更明显。低PLP与PLP依赖通路失调相关,肝移植后低B6状态持续存在,并独立预测非移植PSC患者和移植后复发患者的无肝移植生存期缩短。

要点

  • 不同队列中17-38%的PSC患者PLP水平低于维生素B6缺乏的生化定义。
  • 低PLP独立预测非移植PSC患者和移植后复发患者的无肝移植生存期缩短。
  • 肝移植后低维生素B6状态持续存在,且与PLP依赖通路失调相关。

核心结论

  • 伴有代谢失调的低维生素B6状态是PSC的持续特征,PLP是PSC和复发疾病中无肝移植生存期的强预后生物标志物,作者认为维生素B6缺乏可能修饰疾病,为评估B6状态和测试补充剂提供了依据。

研究设计与样本

  • 采用靶向液相色谱-串联质谱法,在来自不同地理区域的横断面队列(共373例PSC患者和100例健康对照)中测量B6维生素体和B6相关代谢变化。
  • 纳入纵向PSC队列(n=158),在肝移植前和移植后系列采样,并纳入无PSC的炎症性肠病(n=51)或原发性胆汁性胆管炎(n=100)作为疾病对照。
  • 使用Cox回归评估PLP对肝移植前后结局的附加预测价值。

主要发现

  • 在不同队列中,17-38%的PSC患者PLP水平低于维生素B6缺乏的生化定义。
  • 维生素B6缺乏在PSC中比无PSC的炎症性肠病和原发性胆汁性胆管炎更明显。
  • 低PLP与PLP依赖通路失调相关,低B6状态在肝移植后大部分持续存在。
  • 低PLP独立预测非移植PSC患者和移植后复发疾病患者的无肝移植生存期缩短。

临床怎么用

  • 原文结论指出,研究结果为测量维生素B6以及研究维生素B6补充或调节肠道微生物群落能否改善PSC患者结局提供了依据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: We previously demonstrated that people with primary sclerosing cholangitis (PSC) had reduced gut microbial capacity to produce active vitamin B6 (pyridoxal 5'-phosphate [PLP]), which corresponded to lower circulating PLP levels and poor outcomes. Here, we define the extent and biochemical and clinical impact of vitamin B6 deficiency in people with PSC from several centers before and after liver transplantation (LT). METHODS: We used targeted liquid chromatography-tandem mass spectrometry to measure B6 vitamers and B6-related metabolic changes in blood from geographically distinct cross-sectional cohorts totaling 373 people with PSC and 100 healthy controls to expand on our earlier findings. Furthermore, we included a longitudinal PSC cohort (n = 158) sampled prior to and serially after LT, and cohorts of people with inflammatory bowel disease (IBD) without PSC (n = 51) or with primary biliary cholangitis (PBC) (n = 100), as disease controls. We used Cox regression to measure the added value of PLP to predict outcomes before and after LT. RESULTS: In different cohorts, 17-38% of people with PSC had PLP levels below the biochemical definition of a vitamin B6 deficiency. The deficiency was more pronounced in PSC than in IBD without PSC and PBC. Reduced PLP was associated with dysregulation of PLP-dependent pathways. The low B6 status largely persisted after LT. Low PLP independently predicted reduced LT-free survival in both non-transplanted people with PSC and in transplant recipients with recurrent disease. CONCLUSIONS: Low vitamin B6 status with associated metabolic dysregulation is a persistent feature of PSC. PLP was a strong prognostic biomarker for LT-free survival both in PSC and recurrent disease. Our findings suggest that vitamin B6 deficiency modifies the disease and provides a rationale for assessing B6 status and testing supplementation. IMPACT AND IMPLICATIONS: We previously found that people with PSC had reduced gut microbial potential to produce essential nutrients. Across several cohorts, we find that the majority of people with PSC are either vitamin B6 deficient or have a marginal deficiency, which remains prevalent even after liver transplantation. Low vitamin B6 levels strongly associate with reduced liver transplantation-free survival as well as deficits in biochemical pathways dependent on vitamin B6, suggesting that the deficiency has a clinical impact on the disease. The results provide a rationale for measuring vitamin B6 and to investigate whether vitamin B6 supplementation or modification of the gut microbial community can help improve outcomes for people with PSC.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Braadland PR, Bergquist A, Kummen M, et al. Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation. J Hepatol. 2023. PMID: 37328069. doi:10.1016/j.jhep.2023.05.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。